Fact-checked by Grok 2 weeks ago

Durex


Durex is a British brand of condoms, personal lubricants, and related intimate products owned by the multinational consumer goods company Reckitt. The brand originated with the London Rubber Company, established in 1915 by L.A. Jackson to import and distribute condoms and barber supplies, and the Durex name—derived from "Durability, Reliability, and Excellence"—was registered in 1929 for its seamless latex condoms. Over its nearly century-long history, Durex has pioneered manufacturing advancements, including electronically tested condoms for quality assurance and the first lubricated variants, establishing itself as the world's top-selling condom brand with products available in over 150 countries. In 2010, Reckitt acquired SSL International, Durex's parent at the time, in a £2.5 billion deal that integrated the brand into its health portfolio.

History

Founding and Early Development (1915–1940s)

The London Rubber Company was established in 1915 by L.A. Jackson, a immigrant, initially operating as a wholesaler importing condoms and barber supplies from manufacturers in the United States and . The company began from modest operations tied to a tobacconist-hairdresser shop, focusing on distributing rubber goods amid growing demand for prophylactic devices following disruptions in European supply chains during . Early sales emphasized disposable condoms, which were novel at the time compared to reusable alternatives made from animal intestines or fabric. In 1929, the company introduced the Durex brand name, an acronym for "Durability, Reliability, and Excellence," marking its shift toward branded marketing of sheathed condoms produced with emerging rubber techniques. This coincided with the adoption of -based production methods, which improved elasticity and reliability over earlier cement-dipped rubber variants. By the early , manual latex dipping processes yielded approximately 2 million condoms annually, but output remained limited by labor-intensive hand-molding. Key advancements in the stemmed from innovations by Lucian Landau, a rubber technology student and immigrant in , who designed and installed automated dipping machines for the Durex facility. These machines enabled seamless liquid latex application, drastically scaling production while reducing defects and costs, positioning the company as a leader in mass-manufactured prophylactics before . Despite wartime rubber shortages in the late and early 1940s, the foundational infrastructure supported sustained operations, with Durex gaining recognition for consistent quality in a market dominated by imported or rudimentary products.

Post-War Expansion and Innovations (1950s–1990s)

Following , the London Rubber Company, which manufactured Durex condoms, expanded production amid rising demand driven by post-war and changing social attitudes toward contraception in and abroad. By the early , the company had automated much of its manufacturing processes, transitioning from semi-mechanized dipping techniques to more efficient methods that supported increased output for domestic and export markets. In 1953, Durex pioneered electronic testing for integrity, a breakthrough that replaced manual water submersion tests and improved across batches, enabling reliable scaling for global distribution. The 1950s also saw Durex introduce its first moistened, lubricated , enhancing user comfort and addressing a key limitation of dry products, which facilitated broader consumer acceptance. Into the 1960s, innovations continued with the launch of the first anatomically shaped in 1969, designed to better conform to male for improved fit and sensation. That decade marked further expansion, including the opening of the UK's first company-sponsored clinic in 1962 and integration into the for distribution, which boosted accessibility and sales volumes. By the 1970s, Durex became the first brand to conduct global campaigns across multiple countries, capitalizing on the to penetrate international markets and solidify its position as a leading exporter. Through the and , Durex diversified its product line with innovations like the first spermicidally lubricated in and, later, colorful and flavored variants in , responding to evolving consumer preferences for variety and . The company standardized a quality seal in the to assure consistent standards across production sites, while introducing latex-free options in 1997 to accommodate allergies, broadening its appeal. These developments, coupled with ongoing into rubber processing and testing, supported Durex's dominance in supply chains and its expansion into over 150 countries by the late , though specific sales figures from the era remain proprietary.

Modern Era and Acquisitions (2000s–Present)

In 2001, under , Durex launched Pleasuremax, the first condom featuring both ribbed and dotted textures designed to enhance stimulation for both partners. This innovation marked a continuation of in a competitive market, emphasizing sensory enhancements alongside protective efficacy. Throughout the , Durex maintained its focus on research-driven improvements, including advancements in formulations and technologies to improve reliability and , though specific filings from this period highlight incremental refinements rather than revolutionary shifts. A pivotal corporate event occurred in July 2010, when agreed to acquire SSL International, Durex's parent company, for £2.54 billion (approximately $3.9 billion at the time), with the deal completing in November 2010. This transaction integrated Durex into portfolio of consumer health brands, providing expanded distribution networks and resources, while SSL's annual exceeded $1.2 billion as of March 2010, driven largely by Durex and Scholl products. Post-acquisition, Reckitt rebranded to in 2021, but Durex operations remained focused on intimate wellness, benefiting from synergies in global supply chains and R&D investment. Under Reckitt ownership, Durex solidified its position as the world's top-selling brand, with over 90 years of market presence supporting ongoing expansions into emerging markets. growth accelerated in the 2010s and 2020s, particularly in , where demand for Durex products rose amid and health awareness campaigns; for instance, in Q3 2025, Reckitt reported like-for-like net revenue growth of 13.5% for its intimate wellness category, including Durex, with volume up 2.6% and strong performance in . Challenges included regulatory scrutiny on product claims and competition from generic brands, yet Durex's emphasis on quality testing—exceeding ISO standards—sustained consumer trust, with no major recalls reported in this era. Recent initiatives under Reckitt have included and adaptations, contributing to volume recovery post-2020 restrictions.

Corporate Ownership

London Rubber Company Origins

The London Rubber Company (LRC) was founded in 1915 by Lionel Alfred Jackson, a third-generation Russian-Jewish immigrant, as a wholesaling operation in . Initially based at 3 Mincing Lane, the company imported disposable condoms and barber supplies from manufacturers in the United States and , distributing them through a small tobacconist-hairdresser . This venture capitalized on growing demand for rubber goods amid early 20th-century advancements in and processing, though LRC focused on importation rather than domestic in its first years. Jackson's enterprise emerged in a regulatory environment where condoms were legal but socially stigmatized, often sold discreetly as "French letters" or via barbers who provided intimate services. By the mid-1920s, LRC had expanded into manufacturing, developing seamless dipped-latex condoms using innovative machinery, though primary credit for the "doctor blade" dipping process—a key advancement for thinner, more reliable products—has been attributed to Lajos Farkas, a Hungarian-Jewish who contributed to the company's technical breakthroughs after arriving in around 1912. Historical accounts, including Borge's analysis in Protective Practices, emphasize LRC's rapid scaling from import wholesaling to becoming the UK's leading condom producer by the , driven by Jackson's despite debates over attribution. In 1929, LRC launched the Durex brand—derived from "Durability, Reliability, Excellence"—to its electrically tested condoms, which featured improved seamlessness and reliability compared to earlier stitched varieties. This branding initiative positioned LRC as a in quality-controlled prophylactics, with production shifting to a dedicated factory in by the 1930s, laying the foundation for postwar dominance in the . Early challenges included wartime rubber shortages and disruptions, yet LRC's focus on empirical testing and material innovation ensured its survival and growth.

Acquisition by Reckitt Benckiser

In 2010, Reckitt Benckiser Group plc, an Anglo-Dutch multinational consumer goods company, agreed to acquire , the owner of the Durex brand, for £2.54 billion in cash. The deal, announced on July 21, represented a 33% premium over SSL's closing share price the previous day and aimed to strengthen Reckitt Benckiser's health and personal care portfolio by integrating Durex condoms alongside brands like Scholl footwear. had previously resulted from the merger of the London Rubber Company (Durex's originator) with Seton Healthcare and Scholl in the late 1990s and early 2000s, positioning it as a specialized player in sexual health and consumer medical products. The transaction faced regulatory scrutiny, including approvals from the and antitrust authorities in regions like , but proceeded without significant divestitures. Completion occurred on October 29, 2010, after shareholder approval and clearance from competition regulators, marking Benckiser's entry into the global market and adding Durex's established leadership in sexual wellness products to its lineup of household essentials like and . Post-acquisition, Benckiser projected annual cost synergies of approximately £100 million by the end of 2012, driven by efficiencies, shared marketing resources, and expanded distribution in emerging markets such as and , where Durex held strong positions. The move diversified Benckiser's revenue streams beyond cleaning and over-the-counter pharmaceuticals, with Durex contributing to growth in the higher-margin consumer health segment, which accounted for a significant portion of SSL's £700 million annual sales at the time. No major operational disruptions were reported immediately following the integration, and Durex retained its autonomy under Benckiser's decentralized structure.

Products and Technology

Core Condom Offerings

Durex's core offerings center on natural rubber latex intended for barrier protection against and sexually transmitted infections, with variants engineered for enhanced sensation, durability, or compatibility. These products undergo rigorous manufacturing standards, including electronic testing for defects, a process Durex adopted early in its history to ensure reliability exceeding regulatory requirements. Standard offerings include basic lubricated, teat-ended condoms in regular fit (nominal width approximately 52-56 mm), available in packs for individual or shared use. Specialized thin variants prioritize sensitivity: Thin Feel provides reduced thickness for better ; Ultra-Thin Feel offers even greater thinness; and Intimate Feel combines extra-thin material with additional lubrication. Textured models incorporate physical features for stimulation, such as ribbing in Tickle Me condoms or dots in Excite Me, while Pleasure Me combines both for dual external sensation. Delay options like Mutual Climax or Performax Intense feature benzocaine-infused internal to desensitize and extend duration, paired with external texturing. Extra Safe variants add marginal thickness (under 0.1 mm more than standard) for reassurance without compromising feel. For size accommodations, close-fit (narrower width for snugger hold), regular, and extra-large (wider for comfort) options exist across lines, with non-latex alternatives like Real Feel mimicking performance for latex-allergic users—transparent, lubricated, and teat-ended with a 56 mm nominal width.

Lubricants and Complementary Products

Durex introduced its Durex Play line of personal lubricants in 2003 as an extension of its intimate wellness portfolio. These water- and silicone-based formulations primarily aim to minimize friction, improve comfort, and amplify sensory experiences during sexual activity, while maintaining compatibility with latex condoms and most sex toys. Water-based lubricants dominate the Durex Play offerings, including the & Play 2-in-1 series, which functions as both a full-body gel and intimate lubricant. Specific variants incorporate for soothing hydration or ylang ylang oil to promote relaxation and . Flavored options, such as cherry-scented gels, support oral play by providing taste enhancements without compromising efficacy. These products absorb readily into , reducing residue, and are pH-balanced to align with natural vaginal conditions. Silicone-based lubricants from Durex offer prolonged glide, resisting wash-off in water and suiting extended sessions, though they require silicone-safe to avoid material degradation. Complementary gels, like the Intense Orgasmic variant, target clitoral and vulval through ingredients that boost blood flow and sensitivity, often applied pre-intercourse for heightened response. Beyond lubricants, Durex provides complementary intimate accessories, including vibrating cock rings for enhanced maintenance and mutual , bullet vibrators for targeted clitoral use, anal plugs for progressive exploration, and masturbatory sleeves for solo or partnered play. These integrate with Durex lubricants to facilitate smoother insertion and prolonged enjoyment, with many featuring adjustable vibrations or ergonomic designs.

Material and Design Innovations

Durex pioneered lubricated condoms in the 1950s, marking an early advancement in design by applying a moistening agent to reduce and improve during application and use. This innovation addressed common complaints about dry condoms, enhancing comfort without compromising barrier integrity. In , Durex introduced electronic testing as the first manufacturer to implement 100% automated quality checks for holes, strength, and flexibility, replacing manual water-dipping methods and reducing defect rates through precise voltage detection of imperfections in . This technological shift elevated manufacturing standards, with subsequent models maintaining this testing protocol to ensure reliability. The 1960s saw Durex develop anatomically shaped condoms, featuring a contoured form with a tip to better conform to penile , minimizing slippage and maximizing compared to straight-walled predecessors. This design refinement, patented by the London Rubber Company, improved fit and sensation, influencing industry norms for ergonomic condom profiles. Material innovations expanded in 1997 with the launch of polyurethane condoms, the world's first commercial polyurethane male condoms, offering a non-latex alternative for those with ; the synthetic provided greater elasticity, thinner gauging potential, and heat transmission superior to natural while maintaining comparable tensile strength. These condoms addressed limitations of natural rubber , such as allergy risks affecting up to 1-6% of users, though early studies noted slightly higher breakage rates in some polyurethane variants under stress tests. Subsequent non-latex developments included formulations in products like Avanti Bare Real Feel, a synthetic material mimicking natural latex's elasticity and skin-like tactility but without proteins causing allergic reactions; condoms transmit body heat more effectively and are positioned as a "next-to-nothing" feel option, with nominal widths around 56mm and standard lubrication. Clinical profiles confirm their in preventing and STIs akin to latex, though real-world depends on correct usage. Design-focused enhancements continued with the 2001 Pleasuremax line, the first Durex condoms combining raised ribs and dots along the surface to stimulate both partners, integrated with lubricated for heightened sensory feedback without altering core . In 2016, the Invisible series debuted as among the thinnest condoms available, using advanced techniques for ultra-fine gauging (approximately 0.045mm thick) to maximize sensitivity while retaining strength verified through electronic testing. These iterations reflect iterative refinements in processing and molding, prioritizing minimal material interference with natural sensation.

Market Position

Global Market Share and Sales

Durex holds a dominant position in the global market, with estimates placing its at around 28% according to reports. Company statements from its owner, , describe Durex as occupying approximately 40% of the worldwide market, particularly strong in , , and . These figures reflect Durex's status as the leading brand globally, ahead of competitors like , though exact shares vary by region and measurement methodology across market research firms. Specific sales revenue for Durex is not itemized in 's public financials, as it falls within broader categories such as self-improvement products in the portfolio. However, reported strong performance for Durex in its Q3 results, contributing to 13.5% like-for-like net revenue growth in the self-improvement segment to £375 million, driven by volume increases and pricing, with notable gains in . Overall, 's net revenue reached approximately €14.6 billion in 2023, with intimate brands like Durex supporting growth in emerging markets amid a global market valued at USD 11.59 billion that year. The condom industry's total size projections differ across analysts, ranging from USD 5.79 billion in 2024 (Fortune Business Insights) to USD 7.9 billion in 2023 (Global Market Insights), but Durex's leadership persists through premium positioning and innovation, sustaining double-digit growth in key categories despite economic pressures.

Regional Variations and Challenges

Durex exhibits significant regional variations in market penetration and product adaptation, driven by differing cultural attitudes toward sexual health and contraception. In the region, which accounted for over 34% of global revenue in 2023, usage remains low in areas like countries, where estimates indicate only one in ten individuals use s regularly, necessitating indirect marketing strategies focused on pleasure rather than explicit protection. In contrast, and show more mature markets with low single-digit category growth and flat sales, respectively, as of the third quarter of 2025, where Durex competes amid higher awareness but faces declining intimate occasions in some locales like the , ranking 33rd out of 36 countries in purchase rates with only 15% of respondents reporting buys. To address these disparities, Durex tailors offerings, such as introducing flavored, colored, or shaped variants in competitive Asian markets like , where local brands like Okamoto and Sagami dominate. Emerging markets, particularly in and , have propelled 's like-for-like sales growth to 15.5% in the third quarter of 2025, offsetting stagnation in developed regions, with strong Durex performance in highlighting adaptation to local preferences through and promotion adjustments. However, cultural barriers persist globally; in conservative Central countries, price sensitivity and societal limit purchases, while in and , entrenched taboos hinder commercial uptake despite efforts to enhance accessibility. Marketing must vary by national perceptions of sex, with more subdued approaches in restrictive societies to avoid backlash. Key challenges include pervasive counterfeiting, which undermines trust and safety, particularly in developing regions. In , nearly half of commercially available condoms were found to be of poor quality in 2014, exacerbating risks, while Chinese operations produced fakes under Durex branding valued at US$7 million as of 2018 raids. Similar seizures occurred in (600,000 units in 2025), the (2005 and 2007), and Trinidad (2019), often involving substandard materials that fail during use. Regulatory hurdles, disruptions, and low awareness in low-income areas further complicate expansion, with issues like allergies and breakage rates amplifying risks in underserved markets. These factors demand ongoing vigilance, as counterfeit prevalence spans from to the Pacific and beyond, threatening efficacy.

Marketing and Branding

Advertising Evolution

Durex's advertising originated in the late following the brand's registration in 1929 by the London Rubber Company, emphasizing durability, reliability, and quality through discreet print media targeted at and functional benefits amid prevailing societal taboos on contraception. Early campaigns avoided explicit sexual imagery, focusing instead on technical assurances like strength testing to appeal to pragmatic consumers in a conservative era. By the , Durex pioneered global as the first brand to promote across multiple countries, shifting toward broader engagement. A pivotal milestone came in 1979 with the "Closer Encounters" billboard campaign in , which depicted intimate couples to promote contraceptive and marked a transition from purely functional messaging to evoking relational closeness, aligning with post-1960s . This era's approach reflected growing acceptance of condoms for pleasure alongside prevention, though still constrained by broadcast regulations. The 1990s and early 2000s saw expansion into digital and television , beginning with Durex's launch of the first brand website in 1996 and global sexual surveys in 1998 to inform culturally attuned campaigns. In markets like upon entry in 1997, initial ads grappled with taboos by prioritizing before evolving to youth-targeted humor. UK television returned in 2002 after a 15-year with spots for the "easy-on" , followed by humorous 2001 ads featuring pursuits to blend with levity. Subsequent decades emphasized sex-positive branding, with 2010's relaxed rules enabling subtle TV visuals like drifting wrappers and a rebrand combating porn stereotypes via manifestos on and . integration, including pun-laden memes and pandemic-era intimacy promotions, further democratized engagement, prioritizing stigma reduction over mere product sales. This progression underscores a causal shift from regulatory and cultural constraints to proactive , backed by data-driven insights like annual reports since 2005.

Campaigns and Public Engagement

Durex has conducted various campaigns emphasizing and intimacy exploration, often leveraging humor and cultural relevance to engage diverse audiences. A notable example is the 2024 "Explorers" , which encouraged partners to explore each other's desires and fantasies to enhance intimacy, positioning the brand as a facilitator of about sexual . In , Durex collaborated with Arabia in 2023 to establish a , fostering discussions on sexual among young people and earning a silver award for building brand affinity in a conservative market. Public engagement efforts include partnerships focused on sexual health advocacy. In 2023, Durex launched the Global Initiative on Young People's Sexual Rights and Health in collaboration with the University of Southern California's Institute for Inequality in Global Health, aiming to advance research and policy on youth sexual well-being worldwide. The (Durex™)RED campaign targeted with educational content on and STIs, promoting practices through and influencer outreach to raise awareness and drive behavioral change. Additionally, in 2022, Durex supported the Condom Alliance's partnership with the MASH Project Foundation for the "Break The Wall" initiative, which addressed intimate well-being and through community programs in regions with high stigma around contraceptive use. The brand has also prioritized inclusivity in public outreach, such as annual support for celebrations by partnering with , an organization advocating for LGBTQ+ rights, to promote sexual equality and access to protection regardless of orientation. These initiatives often integrate digital advertising with broader societal goals, like aligning humorous promotions with UN on health, as seen in campaigns that use wit to destigmatize usage without compromising educational intent. Overall, Durex's engagement strategies blend commercial promotion with verifiable health impacts, though effectiveness varies by cultural context and measurement of long-term behavioral shifts remains data-limited in public reports.

Safety and Effectiveness

Clinical Data and Reliability Studies

A 1997 controlled clinical trial assessed the reliability of Durex Ramses lubricated latex condoms through 4,637 uses by 92 monogamous couples motivated to prevent pregnancy. Total breakage occurred in 0.41% of instances (19 cases), comprising 0.13% nonclinical breaks before intercourse and 0.28% clinical breaks during or immediately after intercourse; complete slippage affected 0.63% of uses (29 cases), yielding a combined clinical failure rate of 1.04%. These figures were lower than in most contemporaneous studies, except one involving female sex workers, underscoring effective performance under optimal conditions of experienced, consistent application. Aggregated data from multiple studies spanning 1997 to 2020 on (NRL) variants, including Durex products, report average clinical breakage rates of 1.41% (with 95% confidence intervals varying by design) and slippage rates of 1.95%, aligning with expectations for compliant condoms in controlled settings. Independent post-market surveillance from 2017 to 2022 logged breakage or slippage incidents at 0.150 per million units, with associated pregnancies at 0.039 per million and STI transmissions at 0.034 per million, reflecting rare mechanical issues in broad distribution. Durex condoms adhere to ISO 4074:2015 standards for NRL male condoms, which require package integrity, absence of holes (via electronic testing), minimum burst volumes (18 ml for nominal width ≤52 mm), tensile strength (>12 ), and simulated simulations without failure, as verified through batch testing exceeding regulatory minima. Comparative trials of ultrathin Durex variants (e.g., 42 µm thickness) demonstrate equivalence to standard gauges (55–70 µm) in failure rates, with no compromise in barrier integrity despite reduced material.00161-1/fulltext) Reliability extends to non-latex options, such as Durex synthetic models, where clinical failure rates match latex benchmarks in head-to-head evaluations, supporting versatility for latex-allergic users without elevated risk of breakage or slippage. Overall, from these studies indicates mechanical reliability exceeding 98% in clinical contexts, though real-world efficacy against (typically 13–18% failure) or STIs hinges on user adherence rather than inherent product defects.

Quality Issues and Recalls

In July 2018, Benckiser, the manufacturer of Durex condoms, initiated recalls in the , , and other regions for ten specific batches of Durex Real Feel non-latex condoms and Durex Latex Free condoms after internal testing revealed failures in shelf-life durability assessments. The affected products, produced earlier that year, did not meet burst pressure standards following simulated three-year storage conditions, posing a risk of tearing or leaking that could compromise protection against and sexually transmitted . The company described the action as precautionary, emphasizing that no other Durex products were impacted and urging consumers to check batch numbers and return affected items for refunds. Similar recalls extended to and later in 2018 for batches of Durex Real Feel Extra Lubricated 10-count and 20-count packs, which also failed equivalent durability tests. In , the recall affected products with expiry dates up to June 2021, with classifying it as a Type II recall for potential health risks but no reported adverse events at the time. These incidents were isolated to non-latex variants and attributed to manufacturing variations in specific lots, not systemic flaws, as confirmed by post-recall statements from the company indicating compliance restoration through enhanced quality controls. In the United States, the issued Class II recalls for certain Durex Pleasure Pack condoms in 2019 and earlier, primarily due to incomplete packaging labeling omitting details on the active ingredient , rather than material defects. These recalls, classified as moderate-risk with low probability of serious health consequences, were terminated by March 2021 after corrective actions, with no evidence of breakage or efficacy failures linked to the products. Allegations of individual product failures have occasionally led to legal claims, such as a 2000 UK case where a sought damages for attributed to a defective under the Consumer Protection Act 1987; the court rejected the claim, finding insufficient evidence of manufacturing defect. No large-scale lawsuits or confirmed widespread defects have been documented beyond batch-specific recalls, and Durex products have generally met regulatory standards in independent testing, though the 2018 events highlighted vulnerabilities in non-latex formulations under prolonged storage.

Controversies and Criticisms

In 2018, Benckiser, the manufacturer of Durex condoms, initiated recalls for multiple batches of Durex Real Feel and Durex Latex Free condoms across several countries, including , , and the , after the products failed to meet required burst pressure specifications during shelf-life testing. These non-latex, polyisoprene-based products were withdrawn due to a heightened of tearing or leaking, potentially compromising their contraceptive and barrier efficacy. The affected batches, such as those with expiry dates up to 2021, underwent early market removal to mitigate risks, with consumers advised to return products for refunds. The U.S. classified related incidents as Class 2 device recalls, including one in 2016 for Durex Pleasure Packs lacking proper labeling of the active ingredient and another for batches failing the 1.0 kPa burst pressure threshold. Analysis of consumer-returned broken Durex over a seven-year period indicated that failures primarily resulted from blunt puncture rather than material , with overall breakage rates for variants typically ranging from 0.4% to 2% in clinical use. These events highlighted vulnerabilities in synthetic condom formulations under storage conditions, though manufacturer testing protocols generally affirm low rates under ideal use. Legal responses to Durex product failures have been limited but include claims under defective product statutes. In 2000, a woman filed a against Durex's manufacturer under the Consumer Protection Act 1987, seeking £120,000 in damages after a split during use, allegedly leading to ; the case centered on claims of defect despite proper usage. Such suits require proving the product's defectiveness independent of user error, as condom efficacy studies emphasize that typical-use failure rates, including breakage and slippage, hover around 2% annually due to combined factors like application and storage. No large-scale class actions against Durex for breakage have been widely reported, with legal recourse often hinging on batch-specific from recalls rather than systemic flaws. Benckiser has responded to recalls by enhancing quality controls and issuing public advisories, prioritizing voluntary withdrawals over regulatory mandates.

Ethical Debates on Promotion and Usage

Critics have argued that Durex's advertising campaigns often promote in ways that undermine traditional moral values, as seen in the 2003 UK poster featuring the slogan "Roger More," which was banned by the Advertising Standards Authority for being offensive and implying . Similar concerns arose with Durex's XXL condom ads in 2016, criticized for vulgarity and objectification, including imagery perceived as encouraging violence or reducing women to body parts, prompting public backlash in media outlets questioning the ethics of such . Ethical debates intensify around exposure to , with complaints to regulatory bodies highlighting risks of premature ; for instance, a South African Advertising Regulatory Board case against a Durex ad cited parental worries that it could mislead children and infringe on families' rights to control timing. In , a 2014 Ad Standards review of Durex gel promotions dismissed child exposure claims but acknowledged debates over whether such ads normalize adult products for minors unfamiliar with their purpose. Proponents of promotion counter that condoms reduce unintended pregnancies and STIs among young people, yet empirical studies on effects remain mixed, with some indicating shock ads for controversial items like condoms can alienate audiences valuing restraint. In culturally conservative regions, Durex's strategies face accusations of clashing with religious and societal norms; ads in have been flagged for content opposing and Islamic values, leading to calls for restrictions. China's government ban on television since the early forced Durex to digital platforms, sparking netizen controversies over "sex well-being" campaigns perceived as eroding traditional ethics. These tensions reflect broader causal debates: while promotion empirically correlates with higher usage and lower rates in targeted populations, opponents contend it incentivizes behavior over , prioritizing individual pleasure against communal stability without robust long-term data isolating causation from .